Key Players
Competitive Landscape
Competition in fall-prevention nutrition products runs through four business models: clinical nutrition manufacturers, consumer supplement brands, specialized medical-nutrition companies and upstream ingredient developers. Finished-product companies compete on adherence and care access while ingredient groups compete on protein quality and formulation flexibility for frailty or recovery nutrition.
Fresenius Kabi made research capacity a clearer competitive lever in June 2025 by expanding its enteral-nutrition R&D center in Gurugram. Nestle Health Science broadened that direction in November 2025 through university collaborations focused partly on healthy longevity. Companies now compete on formulation evidence and the clinical support required to sustain use.
Company developments mapped to drivers, trends and opportunities (2026-2036)
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| In December 2025, Otsuka Pharmaceutical launched a frailty-prevention support module within its FACEDUO VR program. | Earlier frailty recognition increases referrals into nutrition and physical-activity support. | Prevention programs are moving toward combined screening and behavior support. | Nutrition brands can partner with community programs that identify functional decline earlier. |
| In October 2025, Glanbia launched three Optimum Nutrition micronised creatine powder flavors in the UK and Europe. | Older adults and active consumers are seeking muscle-support formats that fit daily routines. | Muscle-health positioning is broadening beyond sports-only audiences. | Protein and muscle-support brands can build adjacent offers for healthy-aging consumers. |
| In July 2025, Medtrition launched Expedite Grape as a new flavor within its clinical nutrition portfolio. | Flavor fatigue can reduce adherence during longer nutrition interventions. | Clinical nutrition portfolios are widening sensory choice without changing care workflows. | Revenue is available from repeat-use formats that reduce taste fatigue in institutional care. |
Abbott, Arla Foods Ingredients and dsm-firmenich also address adult muscle nutrition, medical-nutrition ingredients and healthy-longevity formulation support outside the three mapped developments.
Source: Future Market Insights, Fall-Prevention Nutrition Product and Clinical Nutrition Market Reports, 2026-2036.
Together the leading companies cover consumer supplementation, oral and enteral nutrition, muscle-support formulation and frailty programs used before or after a fall.
Who leads the fall-prevention nutrition product market?
Abbott, Nestle Health Science and Danone Nutricia have the broadest clinical-nutrition positions, while Pharmavite and Haleon have stronger consumer bone-health supplementation routes.
Which suppliers have documented qualification or quality approvals?
Meiji provides a documented qualification example through its March 2025 Mini Cup release, which identifies Consumer Affairs Agency authorization for qualifying balanced nutrition products.
Which companies provide recovery and muscle-support nutrition products?
Abbott, Nestle Health Science, Danone Nutricia, Medtrition and Fresenius Kabi provide nutrition platforms addressing protein intake or clinical recovery needs.
Which suppliers serve North America and Europe?
Abbott and Nestle Health Science serve both regions broadly, while Fresenius Kabi and Glanbia extend clinical or muscle-nutrition coverage through international operating networks.
Representative Company Overview
| Company | Positioning | Verified Development |
|---|---|---|
| Abbott | Global adult-nutrition producer with strong muscle-health and oral nutrition positioning. | In April 2025, Abbott disclosed an Ensure Max Protein partnership with the Professional Pickleball Association. |
| Nestle Health Science | Global consumer-health and medical-nutrition group serving healthy aging and clinical nutrition. | In November 2025, Nestle Health Science began collaborations with three universities focused partly on healthy-longevity nutrition innovation. |
| Fresenius Kabi | Global clinical-nutrition company with enteral nutrition development and care-setting reach. | In June 2025, Fresenius Kabi opened an expanded enteral-nutrition R&D center in Gurugram, India. |
| Medtrition | US clinical-nutrition specialist serving hospitals and long-term care with modular nutrition products. | In July 2025, Medtrition launched Expedite Grape as a new clinical nutrition flavor. |
| Arla Foods Ingredients | Upstream specialized-nutrition ingredient producer that sits at the edge of finished fall-prevention products. | In December 2025, Arla Foods Ingredients launched Lacprodan CGMP-30 for medical-nutrition protein applications. |
| Glanbia | Performance and health-nutrition group with adjacent muscle-support products for active and older consumers. | In October 2025, Glanbia launched three Optimum Nutrition micronised creatine powder flavors in the UK and Europe. |
| dsm-firmenich | Upstream nutrition and health ingredient group supporting healthy-longevity product development. | In September 2025, dsm-firmenich introduced its Longevity Shift experience and presented its Healthy Longevity platform for SupplySide Global. |
| Otsuka Pharmaceutical | Nutraceutical and health-program company with frailty-prevention activity adjacent to nutrition products. | In December 2025, Otsuka Pharmaceutical launched a frailty-prevention support module within its FACEDUO VR program. |
The companies mapped here illustrate the market structure rather than an exhaustive ranking. Inclusion requires current and verifiable evidence that a company supplies older-adult nutrition products used for bone support, muscle support, clinical recovery or direct frailty management within the defined fall-prevention nutrition product scope. Evidence comes from regulatory approvals, third-party certifications, company announcements, product documentation and public filings. Capabilities are attributed to the stated nutrition product family, ingredient platform or frailty-support service line instead of broader corporate portfolios. Market-share estimates remain proprietary FMI assessments for the forecast period.
